Detection of serum S100protein and tissue polypeptide-specific antigen for diagnosis and treatment of breast cancer

Abstract

Abstract: Objective To investigate the expre ss ions of serum S100 protein and tissue polypeptide-specific antigen (TPS) in bre ast cancer and their clinical implications.Methods Using enzyme-linked immunoso rbent assay, the levels of serum S100 protein and TPS were determined in 48 bre ast cancer patients as well as in 92 control subjects.Results The median level of serum S100 protein and TPS were 0.024 μg/L and 135 U/L respectively in the 48 breast cancer patients, among whom their positive rates were 14.6% (7/48) an d 50% (24/48) respectively; in stage IV patients, their positive rates were 70% (7/10) and 60% (6/10) respectively. The levels of the serum S100 protein and TPS tended to increase as the disease advanced, and serum S100 protein level was s ignificantly higher in patients with distal metastasis than in those with local relapse of the tumor.Conclusion Progressively elevated levels of serum S100 pr otein and TPS signify the deterioration of breast cancer, and can be used to es timate the stage and state of breast cancer.

CLC Number:

R737.9

LUO Rong-cheng, HE Xin-bing, CAI Hong-bing, LI Ai-min. Detection of serum S100protein and tissue polypeptide-specific antigen for diagnosis and treatment of breast cancer[J]. Journal of Southern Medical University, 2004, 24(01): 102-104.

References

[1] 陈国建.影响乳腺癌远期生存率相关因素分析[J].广东医学(J Guangdong Med),2000,21(9):767-8.
[2] 张军一,麦国丰,郑航,等.乳腺癌HER2、EGFR表达与生存期的相关性[J].第一军医大学学报,2003,23(10):1090-3.Zhang Jy,Mai GF,Zhang H,et al. Association between the survival time and high-expression of EGFR and HER-2 in breast cancer[J].J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2003,23(10):1090-3.
[3] 麦国丰,郑航,罗荣城,等.乳腺癌HER2、孕激素受体表达与生存期相关性的研究[J].第一军医大学学报,2003,23(4):372-4.Mai GF,Zheng H,Luo RC,et al. Association of progesterone receptor and HER2 expressions with the survival time of patient with breast cancer[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2003,23(4):372-4.
[4] 但汉雷,赵燕,张健,等.乳腺癌多药耐药细胞人中白细胞抗原和B7分子表达的体外调节[J].第一军医大学学报,2002,22(2):107-10.Dan HL,Zhao Y,Zhang J,et al. In vitroregulation of HLA and B7expression in multidrug-resistant breast cancer cells[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2002,22(2):107-10.
[5] Moore B. A soluble protein characteristic of the nervous system[J].Biochem Biophys Res Commun,1965,19(9):739-44.
[6] Schafer BW,Heizmann CW. The S100 family of EF-hand calciumbinding proteins:functions and pathology[J]. TIBS,1996,21(2):134-40.
[7] Magenni DPs,Orchard GE. Malignant melanoma:Death by image and ignorance,diagnosis by surgical excision and laboratory investigation[J]. Br J Biomed Sci,1999,56(2):134-46.
[8] Jackel A,Deichman M,Waldmann V,et al. S-100β protein in serum,a tumor marker in malignant melanoma-current state of knowledge and clinical experiences[J]. Hantarzt,1999,50(3):250-6.
[9] Sherbet GV,Lakshmi MS. S100A4 (MTS1) calcium binding pwtein in cancer growth,invasion and metastasis[J]. Anticancer Res,1998,18(4A):2415-21.
[10] 丁华野,皋岚湘,邓永江,等.S100,S100a和S100β蛋白在乳腺癌中的表达及诊断意义[J].中国组织化学和细胞化学杂志,1999,8(4):438-42.Ding HY,Gao LX,Deng YJ,et al. S100、S100α and S100β in breast carcinoma end its diagnostic significance[J]. Chin J Histochem Cytochem,1999,8(4):438-42.
[11] Rydlander L,Ziegler E,Bergman T,et al. Molecular characterization of a tissue polypeptide specific antigen epitope and its relationship to human cytokeratin 18[J]. EurJ Biochem,1996,241(2):309-14.
[12] 郑航,何本夫,罗荣城,等.组织多肽特异性抗原在乳腺癌中的临床研究[J].第一军医大学学报,2003,23(8):823-5.Zhaeng H,He BF,Luo RC,et al. Clinical study of serum tissue polypeptide-specific antigen in breast cancer[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2003,23(8):823-5.
[13] Moll R,Franke WW,Schiller D,et al. The catalog of human cytokeratins:patterns of expression in normal epithelia,tumors and cultured cells-Review[J]. Cell,1982,31(1):11-24.
[14] van Dalen A. TPS monitoring in metastatic breast cancer[J]. Int J Biol Markers,1999,14(1):45-8.
[15] Bremer K,Eklund G,Bjorklund B. Notable relationship between the level of tumor marker TPS in serum end survival in breast cancer[J]. Anticancer Res,1996,16(2):905-9.